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Methionine is an essential proteinogenic amino acid that is obtained from the diet.
In addition to its requirement for protein biosynthesis, methionine is metabolized to
generate metabolites that play key roles in a number of cellular functions. Metabolism
of methionine via the transmethylation pathway generates S-adenosylmethionine
(SAM) that serves as the principal methyl (−CH3) donor for DNA and histone
methyltransferases (MTs) to regulate epigenetic changes in gene expression. SAM
is also required for methylation of other cellular proteins that serve various
functions and phosphatidylcholine synthesis that participate in cellular signaling. Under
conditions of oxidative stress, homocysteine (which is derived from SAM) enters
the transsulfuration pathway to generate glutathione, an important cytoprotective
molecule against oxidative damage. As both experimental and clinical studies have
shown that traumatic brain injury (TBI) alters DNA and histone methylation and
causes oxidative stress, we examined if TBI alters the plasma levels of methionine
and its metabolites in human patients. Blood samples were collected from healthy
volunteers (HV; n = 20) and patients with mild TBI (mTBI; GCS > 12; n = 20)
or severe TBI (sTBI; GCS < 8; n = 20) within the first 24 h of injury. The
levels of methionine and its metabolites in the plasma samples were analyzed
by either liquid chromatography-mass spectrometry or gas chromatography-mass
spectrometry (LC-MS or GC-MS). sTBI decreased the levels of methionine, SAM,
betaine and 2-methylglycine as compared to HV, indicating a decrease in metabolism
through the transmethylation cycle. In addition, precursors for the generation of
glutathione, cysteine and glycine were also found to be decreased as were
intermediate metabolites of the gamma-glutamyl cycle (gamma-glutamyl amino acids
and 5-oxoproline). mTBI also decreased the levels of methionine, α-ketobutyrate,
2 hydroxybutyrate and glycine, albeit to lesser degrees than detected in the sTBI group.
Abbreviations: ANOVA, analysis of variance; BCAAs, branched-chain amino acids; BHMT, betaine homocysteine
methyltransferase; CT, computed tomography; DRS, Disability Rating Scale; GC-MS, gas chromatography-mass
spectrometry; GCL, glutamate cysteine ligase; GCS, Glasgow coma scale; GGT, gamma-glutamyl transpeptidase; GGCT,
gamma-glutamyl cyclotransferase; HAM-D, Hamilton depression rating scale; HV, healthy volunteers; LC-MS, liquid
chromatography-mass spectrometry; MAT, L-methionine S-adenosyltransferase; mTBI, mild TBI; ROS, reactive oxygen
species; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SSRIs, serotonin reuptake inhibitors; TBI, traumatic
brain injury; TMB, tetramethylbenzidine.
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Taken together, these results suggest that decreased levels of methionine and its
metabolic products are likely to alter cellular function in multiple organs at a systems
level.
Keywords: concussion, epigenetic changes, metabolomics, protein methylation, S-adenosylmethionine,
transsulfuration
INTRODUCTION
It has been appreciated for more than 30 years that the
resting metabolic expenditure of the severely injured brain is
almost 40% higher than that of the non-injured brain, and
is associated with a negative nitrogen balance (the difference
between nitrogen uptake and nitrogen excretion), suggesting
increased protein catabolism (Clifton et al., 1985). Increasing
enteral nutrition to compensate for the enhanced nitrogen
excretion has shown only partial success (Clifton et al., 1985),
possibly due to poor gut absorption and/or impaired gut motility.
In particular, insufficient availability of essential amino acids
(primarily obtained from the diet) can not only negatively
influence cell survival and function in the injured brain, but
also can impair the function of other organs as well. In addition
to serving as the building blocks for proteins, amino acids
and their metabolites play critical roles in various cellular and
physiological functions (e.g., regulation of cerebral perfusion by
the arginine metabolite nitric oxide). Although a few studies
have measured amino acid levels in traumatic brain injury (TBI)
patients (Aquilani et al., 2000; Jeter et al., 2012, 2013; Vuille-Dit-
Bille et al., 2012), whether the metabolic products of these amino
acids are altered in TBI patients is largely unknown.
Methionine is an essential amino acid for protein
synthesis and is often incorporated as the first amino acid.
Metabolism of methionine occurs by two primary pathways: the
transmethylation and the transsulfuration (Figures 1A, 3A, 4A).
The transmethylation pathway generates S-adenosylmethionine
(SAM), an important methyl donor for the methylation of lipids,
proteins, and nucleotides. For example, SAM-dependent DNA
and histone methyltransferases (MTs) have been found to be
key enzymes in the epigenetic regulation of gene expression
(Cantoni, 1975; Bird, 2007). SAM also donates methyl groups
for the synthesis of phosphatidylcholine, a major phospholipid
component of cell membranes and an important signaling
molecule for both intra- and inter-cellular communication
(Hirata and Axelrod, 1980). In addition to generating SAM,
methionine is required for the synthesis of glutathione via the
transsulfuration pathway. Under conditions of stress, cells use
glutathione to scavenge reactive oxygen species (ROS) in order
to reduce oxidative damage. Both experimental and clinical
studies have shown that TBI causes oxidative damage to the
injured brain, which may be related to decreases in glutathione
availability (Povlishock and Kontos, 1992; Bayir et al., 2002;
Singh et al., 2006; Bains and Hall, 2012). Thus, decreases in the
levels of methionine and/or its metabolic products may underlie
oxidative damage and the progression of TBI pathology and
outcome.
In the present study, we measured the levels of methionine
and several of its metabolites in plasma samples collected within
the first 24 h of their injury from patients who experienced
either a severe (GCS ≤ 8) or mild (GCS > 12) TBI (sTBI or
mTBI). Plasma samples from healthy volunteers (HV) were used
as controls. An acute time point for sample collection was chosen
as experimental studies have shown that robust oxidative damage
and cell death occurs during this period. Our results indicate
that both mild and severe TBI cause significant reductions in
plasma methionine levels. A decrease in the transmethylation
product SAM was observed in sTBI patients, as were the plasma
levels of choline, betaine, and dimethylglycine. The levels of
the transsulfuration metabolite cysteine, as well as the gamma-
glutamyl cycle metabolites (gamma-glutamyl amino acids and
5-oxoproline), were also found to be reduced after sTBI.
Taken together, these results demonstrate that TBI decreases
methionine and its key metabolites, which may alter the
function of multiple organs, and suggest that supplementation
of methionine metabolites may be beneficial for sTBI patients.
MATERIALS AND METHODS
Recruitment of Study Subjects
The University of Texas Health Science Center at Houston
Committee for the Protection of Human Subjects approved the
human subject protocol in accordance with the Declaration
of Helsinki. In total, 60 subjects were recruited and provided
written informed consented for participation in this study. All
subjects were between 14–57 years of age and provided consent
or proxy consent for their participation in this study. None
of the subjects had drug dependency, or had active infections.
Twenty sTBI (GCS ≤ 8), 20 mTBI (GCS ≥ 12), and 20 HV
were recruited for this study. mTBI had no abnormalities on
head computed tomography (CT) scans, but experienced one
or more of the following: loss of consciousness, post-traumatic
amnesia, altered mental status, neurologic deficits, or seizure.
Demographic and clinical information on the study subjects is
provided in Table 1. The predominant causes of all injuries were
motor vehicle accidents and falls.
Sample Collection and Analysis
Seventeen of the 20 HV did not eat after midnight, the
night before sample collection (at least 12 h before sample
collection). The mTBI subjects had a last recorded meal that
was 7.5 ± 4.4 h prior to sample collection. sTBI samples were
collected 15.07 ± 5.0 h after the time of their injury. Blood
samples were obtained within the first 24 h after injury and
were coded to protect anonymity. Samples were collected in
potassium EDTA tubes (Becton Dickinson, Franklin Lakes, NJ,
USA), placed on ice, and processed within an hour of draw.
Plasma was isolated by centrifugation at 4◦C as described by
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FIGURE 1 | Severe traumatic brain injury (sTBI) reduces plasma methionine and metabolism through the transmethylation pathway. (A) Schematic
showing the metabolism of methionine via the transmethylation pathway. Molecules detected and measured are presented in bold text. Key enzymes are indicated
by italic text. The plasma levels of (B) methionine were significantly reduced as a result of TBI. (C) S-adenosylmethionine (SAM) was significantly reduced in sTBI
compared to healthy volunteers (HV) and patients with a mild TBI (mTBI). When the data were segregated by gender, similar changes in both (D) methionine and
(E) SAM were observed in males and females. MAT: methionine adenosyltransferase; MTs: methyltransferases; SAHase: S-adenosyl-L-homocysteine hydrolase.
Horizontal bar indicates mean. ∗p < 0.05.
TABLE 1 | Demographic and clinical data for study subjects.
Group Healthy volunteers Mild TBI Severe TBI
Number of subjects 20 20 20
GCS (24 h of injury) NA 14.85 ± 0.37 3.65 ± 1.2
(intubated)
Injury Severity Score NA 5.4 ± 2.4 27.5 ± 8.2
Age (years) 25.2 ± 6.7 36.1 ± 13.3 25.8 ± 9.8
Female/Male 4/16 6/14 4/16
Hispanic ethnicity 6 3 4
Race
White 16 18 16
African American 3 2 3
Asian 1 0 1
TBI, traumatic brain injury; values in mean ± standard deviation.
the vendor. Aliquots were prepared and frozen at −80◦C until
needed. Plasma was processed by Metabolon, Inc. (Durham,
NC, USA) using a proprietary series of extractions designed to
increase the sensitivity of small molecule detection. Samples were
placed briefly on a TurboVapr (Caliper Technologies Corp.,
Hopkinton, MA, USA) to remove any organic solvent. Each
sample was then frozen and dried under vacuum. The samples
were analyzed by liquid chromatography-mass spectrometry
(LC-MS) or gas chromatography-mass spectrometry (GC-MS)
depending on the analyte being interrogated. Methionine and its
metabolites were identified by comparison to purified standards.
A selection of quality control compounds was added to every
sample. Relative levels of each metabolite were quantified
using Metabolon’s proprietary peak integration software. The
integrated peak values from all subjects were averaged and used
for normalizing the values for each individual subject.
Enzyme-Linked Immunosorbent Assays
(ELISAs)
SAM was measured using a competitive ELISA as described
by the vendor (BioVendor, Asheville, NC, USA). A standard
curve for calculating the abundance of SAM was generated
by serial dilution of a purified standard. The range of the
standards was based on the vendors’ instructions. Standards
and plasma samples (50 µl) were added to a 96-well plate
containing immobilized antibodies specific to SAM. Biotinylated
SAM was immediately added to the well, after which the plate
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was incubated at 37◦C for 1 h. After extensive washing, a
streptavidin-horseradish peroxidase conjugate was added and
incubated for 30min. The plate was washed, and developed using
tetramethylbenzidine (TMB). The reaction was terminated by the
addition of 2N sulfuric acid. The optical density was measured
using a microplate reader at 450 nm. Concentration of SAM in
the plasma was calculated using a 4-parameter logistic curve.
Statistical Analysis
Data was initially evaluated using a Shapiro-Wilk normality test,
followed by a one-way analysis of variance (ANOVA) across
the four subject groups. Any data found to not have a normal
distribution was analyzed using a Kruskal-Wallis ANOVA on
ranks. Groups with differences were identified using a Dunn’s
pairwise comparison as the post hoc test. Differences were
considered significant at p< 0.05, with groups with altered levels
identified using critical p-values calculated after compensation
for multiple comparisons.
RESULTS
Methionine is metabolized by two primary metabolic
cycles: the transmethylation pathway to generate SAM and
homocysteine (Figure 1A); and the transsulfuration cycle to
generate glutathione (Figures 3A, 4A). While not all individual
metabolites of these cycles could be detected and quantified,
intermediate metabolites for all three cycles were detected. Based
on the changes in the levels of these intermediate metabolites,
alterations in the flux of these three pathways can be inferred.
The Methionine (Transmethylation) Cycle
The transmethylation cycle involves the metabolism of
methionine to generate SAM, S-adenosylhomocysteine (SAH),
and homocysteine (Figure 1A). When the relative plasma
levels of methionine were measured in patients with either
sTBI (GCS < 8) or mTBI (GCS > 12) and compared to HV, a
significant change across the groups was detected (F = 44.01,
p < 0.001). Post hoc analysis revealed a significant reduction of
plasma methionine in both mild and severe TBI patients relative
to HV, with greater reductions detected in the sTBI group
(Figure 1B). In contrast, the relative levels of phenylalanine, a
second essential amino acid, were found to be unchanged across
all three groups (F = 1.82, p = 0.17). Methionine is converted to
SAM by L-methionine S-adenosyltransferase (MAT). Although
SAM was not detected by LC/GC-MS, we used a competitive
ELISA to measure the levels of this important methyl donor.
Figure 1C shows concentration of SAM in individual samples.
When analyzed by a one-way ANOVA on Ranks, a significant
decrease (H = 29.44, p < 0.001) in plasma SAM levels was
detected in the sTBI patients compared to the other groups. As
it has been reported that there are gender differences in amino
acid metabolism (Lamont et al., 2003), we next parceled the
methionine and SAM results to examine sex-related differences.
As TBI occurs predominately in males (4:1 male to female ratio),
our recruited study subjects followed this distribution resulting
in 4–6 females in each of our study groups (Table 1). However,
even with this small number of females, we observed that the
changes in methionine appear to be independent of gender
with both males and females showing significant decreases
(F = 17.58, p < 0.001) in plasma methionine in the sTBI group
(Figure 1D). However, due to the reduction in number of
subjects in each group, the difference between the mTBI group
and HV was no longer statistically significant. Plasma SAM
(F = 9.70, p< 0.001) was also found to change similarly in males
and females (Figure 1E), although more error-prone in the
females due to the small number of study subjects. No significant
differences between males and females within any group were
detected.
A number of methyltransferases use SAM as a methyl
donor for DNA, protein and lipid methylation and convert
SAM to SAH (Cantoni, 1975; Grillo and Colombatto, 2008).
SAH is then converted by SAH hydrolase to homocysteine,
which can be used as a substrate to regenerate methionine
(Figure 2A). In this pathway, choline is metabolized to betaine,
which then acts as the methyl donor for the methylation
of homocysteine by betaine homocysteine methyltransferase
(BHMT). During this reaction, homocysteine is converted to
methionine and dimethylglycine. Figure 2B shows the relative
levels of choline in the plasma samples of individual subjects
from all three groups. Plasma choline levels in the sTBI group
were found to be significantly reduced as compared to the other
groups (H = 18.64; p < 0.001). Betaine (trimethylglycine) is
synthesized from choline via a multistep enzymatic pathway.
The plasma levels of betaine were found to be significantly
reduced (F = 8.42; p < 0.001) in the sTBI patients relative
to the HV and mTBI group (Figure 2C). When the plasma
levels of dimethylglycine were interrogated, a significant decrease
(H = 8.76 p = 0.013) in its plasma levels were detected in
the samples from sTBI patients compared to HV, but not
the mTBI group (Figure 2D). Taken together, the decreased
levels of these metabolites indicated decreased flux through the
transmethylation pathway.
The Transsulfuration Pathway
Transsulfuration of homocysteine is essentially an irreversible
reaction that generates cystathionine (via cystathionine
β-synthase), which is further metabolized by cystathionine
gamma-ligase to produce cysteine and alpha-ketobutyrate.
Alpha-ketobutyrate is then reduced by α-hydroxybutyrate
dehydrogenase to generate 2-hydroxybutyrate (Figure 3A).
Although the relative levels of both α-ketobutyrate (Figure 3B;
H = 22.05, p < 0.001) and 2-hydroxybutyrate (Figure 3C;
H = 28.65, p< 0.001) were found to be significantly increased in
the plasma of sTBI patients, cysteine levels showed a significant
reduction (Figure 3D; F = 20.23, p < 0.001). Interestingly,
the levels of cysteine in the plasma of mTBI was found to be
significantly increased relative to HV.
Glutamate cysteine ligase (GCL) ligates cysteine with
glutamate to generate gamma-glutamylcysteine that is then
combined with glycine by glutathione synthase (GS) to generate
glutathione (Figure 4A). Although the relative plasma levels of
glutamate did not significantly change across groups (Figure 4B;
H = 2.21, p = 0.331), the plasma levels of glycine were found to
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FIGURE 2 | sTBI reduces the levels of methyl donors for methionine remethylation. (A) Schematic showing the methylation of homocysteine to generate
methionine. Molecules detected and measured are presented in bold text. Key enzymes are indicated by italic text. The plasma levels of the methyl donors
(B) choline and (C) betaine used in methionine remethylation were significantly reduced in sTBI. (D) The side-product of methionine regeneration, dimethylglycine, is
significantly reduced as a result of sTBI. BHMT: betaine-homocysteine S-methyltransferase. Horizontal bar indicates mean. ∗p < 0.05.
FIGURE 3 | TBI alters methionine metabolism through the transsulfuration pathway. (A) Drawing of the transsulfuration pathway in which homocysteine is
converted to cysteine and alpha-ketobutyrate. Alpha-ketobutyrate is reduced to generate 2-hydroxybutyrate. Molecules detected and measured in the current study
are presented in bold text. Key enzymes are indicated by italic text. Although the plasma levels of both (B) alpha-ketobutyrate and (C) 2-hydroxybutyrate were
significantly elevated in the plasma of sTBI patients compared to other groups, the plasma levels of (D) cysteine were significantly decreased in sTBI patients. In
contrast, the levels of cysteine were significantly increased in the mTBI group. HV: healthy volunteers; mTBI: mild TBI patients; CBS: cystathionine-β-synthase; CSE:
cystathionine γ-lyase; α-HBDH: alpha-hydroxybutyrate dehydrogenase. Horizontal bar indicates mean. ∗p < 0.05.
be significantly reduced in both the mild and severe TBI patients
(Figure 4C; F = 27.61, p< 0.001).
The Gamma-Glutamyl Cycle
A decrease in cysteine and glycine would be expected to result
in a decrease in the levels of glutathione. Unfortunately, plasma
glutathione could not be detected by our mass spectrometry
analysis. In addition to its role in the reduction of oxidative stress,
glutathione is used to facilitate the transport of amino acids
into cells via the gamma-glutamyl cycle (Orlowski and Meister,
1970). This occurs via the conversion of amino acids to gamma-
glutamyl amino acids by gamma-glutamyl transpeptidase (GGT).
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FIGURE 4 | Plasma glycine, but not glutamate levels are reduced as a result of sTBI. (A) Simplified drawing showing the production of glutathione from
cysteine, glycine and glutamate. Glutamate cysteine ligase (GCL) catalyzes the reaction between glutamate and cysteine to produce gamma-glutamylcysteine.
Glutathione synthase (GS) converts gamma-glutamylcysteine and glycine to generate glutathione. Molecules detected and measured in the current study are
presented in bold text. Key enzymes are indicated by italic text. (B) Glutamate levels did not change across any of the subject groups. Horizontal bar indicates
mean. (C) Plasma glycine levels in individual subjects from HV mTBI, and sTBI are shown. The levels of glycine are significantly reduced in the plasma of sTBI
patients compared to all other groups. ∗p < 0.05.
The release of amino acids from gamma-glutamyl amino
acids by gamma-glutamyl cyclotransferase (GGCT) generates
5-oxoproline as an intermediate (Figure 5A). Thus, a decrease
in glutathione availability would be anticipated to result in a
decrease in gamma-glutamyl amino acids and 5-oxoproline. The
relative levels of gamma-glutamylvaline (Figure 5B; F = 13.54,
p < 0.001), gamma-glutamylleucine (Figure 5C; H = 30.48,
p < 0.001), gamma-glutamylisoleucine (H = 23.60, p < 0.001),
gamma-glutamyltyrosine (H = 14.12, p < 0.001), and gamma-
glutamylphenylalanine (F = 4.56, p = 0.015) were found to be
significantly decreased in the plasma of sTBI patients. Consistent
with the decrease in gamma-glutamyl amino acids, 5-oxoproline
was found to be significantly reduced in the plasma of sTBI
patients compared to other groups (Figure 5D; H = 17.66,
p< 0.001).
DISCUSSION
The essential amino acid methionine not only acts as a
building block for protein synthesis, but also serves as the
substrate for the synthesis of key molecules such as SAM
and glutathione. As such, changes in the levels of methionine
metabolites could impact a number of biological processes such
as epigenetic regulation of gene expression and cytoprotection.
Our measurements of methionine and its metabolites in plasma
samples from sTBI, mTBI, and HV revealed four key findings:
(1) the relative plasma levels of methionine and SAM are
significantly reduced in sTBI patients; (2) the levels of cysteine
and glycine, the precursors for the synthesis of glutathione,
are also reduced in sTBI patients; (3) in contrast to that
observed in sTBI patients, the plasma levels of cysteine were
FIGURE 5 | TBI reduces glutathione recycling through the gamma-glutamyl cycle. (A) Simplified schematic showing the enzymes and intermediates for the
gamma-glutamyl cycle. Molecules detected and measured in the current study are presented in bold text. Key enzymes are indicated by italic text. The levels of the
gamma-glutamyl amino acids (B) gamma-glutamylvaline and (C) gamma-glutamylleucine, and the intermediate (D) 5-oxoproline are significantly reduced in the
plasma of sTBI patients compared to HV, and mTBI groups. GGT: gamma-glutamyl transpeptidase; GGCT: gamma-glutamyl cyclotransferase. Horizontal bar
indicates mean. ∗p < 0.05.
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significantly elevated in mTBI; and (4) the relative levels of
several gamma-glutamyl amino acids and 5-oxoproline are
significantly reduced in the plasma of sTBI patients. These
findings are summarized in Figure 6. Taken together, our
findings suggest that the reduced availability of methionine, SAM
and glutathione as a result of sTBI may alter multiple cellular
processes including protein synthesis, epigenetic regulation
of gene expression, cytoprotection, and the cellular transport
of amino acids in multiple organs including the injured
brain.
As methionine is an essential amino acid, its decrease in
both mild and severe TBI patients could have resulted from
a reduction in dietary intake. However, the time from last
meal was comparable for the HV and sTBI groups, with all
groups having not eaten within 7 h of sample collection. Thus,
the changes in methionine levels we observed in TBI patients
may not be solely due to lack of food intake. Previous clinical
studies have shown that sTBI causes a nitrogen imbalance
in which nitrogen excretion exceeds nitrogen uptake (Clifton
et al., 1985), suggesting increased protein break-down. Attempts
to restore nitrogen balance using enteral feeding found that
replacement of 17 g N/day yielded a nitrogen balance of
−9.2 g/day, whereas replacement of 29 g N/day restored nitrogen
balance to −5 g/day (Clifton et al., 1985). Given that the
human body requires up to 1.5 g protein/kg/day in order
to maintain lean body mass and normal protein synthesis
(Bistrian and Babineau, 1998), higher protein loads are likely
required to preserve muscle mass. However, although enteral
hyperalimentation can partially restore metabolic expenditure
FIGURE 6 | Summary illustration of methionine metabolic pathways.
Metabolites of the transmethylation pathway are indicated in red, the
transsulfuration pathway is indicated in blue, and the gamma-glutamyl cycle is
shown in green. Black arrowhead (N) indicates changes in metabolite levels in
the plasma of sTBI patients. Open arrows (4) indicate significant changes
measured in the mTBI patients as compared to HV. Up arrowheads indicate
increased levels, whereas down arrowheads indicate decreased levels.
in sTBI patients, feeding rarely achieves nitrogen balance
resulting in weight loss of up to 15% by the second week
after injury (Clifton et al., 1985). As the principal source of
excreted nitrogen is urea, and urea is generated from the
deamination of amino acids, this suggests that circulating amino
acids levels should also be reduced in TBI patients. Consistent
with this, it has been reported that sTBI patients have low
levels of serum amino acids, including essential amino acids
such as branched-chain amino acids (BCAAs), histidine, and
methionine when measured 2 months after injury (Aquilani
et al., 2000). In addition to chronic reductions in amino acid
levels, the reduced levels of some amino acids have been seen
as early as 24 h after TBI (Jeter et al., 2012, 2013). Irrespective
of the mechanism by which methionine levels are reduced,
decreased methionine availability would be expected to reduce
its brain levels. In support of this, it has been demonstrated
that the administration of intravenous amino acids results in
an increase in their levels in the brain (Lajtha and Mela,
1961).
Only a few clinical studies have examined the consequences
of amino acid supplementation after TBI. Ott et al. (1988)
compared the effects of two different intravenous amino acid
formulations on amino acid levels and nitrogen balance in
sTBI patients. Their results indicated that positive nitrogen
balance could be achieved with early administration of some
combinations of amino acids, although neither the specific
amino acids responsible for this improvement, nor their effect
on outcome was assessed (Ott et al., 1988). BCAAs play
important roles in regulating protein synthesis, gluconeogenesis,
and energy metabolism as well as functioning as a major
source of nitrogen for producing glutamine and nitric oxide
(Fernstrom, 2005; Jeter et al., 2013). Experimental studies
have shown that dietary supplementation of BCAAs improves
cognitive function and can reduce injury-associated sleep
disturbances (Lim et al., 2013; Elkind et al., 2015). Aquilani
et al. (2000) tested if supplementation of BCAAs for 15 days
during rehabilitation (average time from injury: 2 months)
improved outcome, and found that patients receiving BCAAs
had improved cognitive function as indicated by a reduction
in their Disability Rating Scale (DRS) scores. Nägeli et al.
(2014) tested if inclusion of an alanine-glutamine dipeptide
as a part of normal feeding (initiated 3 days after injury)
could be used to increase plasma and brain glutamine levels
without corresponding increases in cerebral glutamate. Although
alanine and glutamine levels in the brain were found to
be increased in the absence of a net increase in cerebral
glutamate, the benefit of this treatment on outcome was
not evaluated (Nägeli et al., 2014). At present, it has not
been determined if supplementation of methionine would
improve outcome in sTBI patients. However, in an animal
model of TBI, administration of methionine was found to
increase neuronal apoptosis via yet unidentified mechanisms
(Akkaya et al., 2014). As we observed that methionine and
a number of its metabolites were reduced as a result of
TBI, supplementation of these or other intermediates may
be beneficial and may reduce complications associated with
methionine administration.
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SAM is a key methyl group donor for methylation
of intracellular molecules including DNA, proteins and
phospholipids (Grillo and Colombatto, 2008). A methyl group
is transferred to these substrates by different methyl transferases.
Methylation of these molecules regulates a number of important
biological processes including epigenetic gene regulation
(via DNA and/or histone methylation), axonal transport (via
microtubule methylation) and plasma membrane integrity and
signal (via phospholipid methylation; Cantoni, 1975; Hirata and
Axelrod, 1980; Bhaumik et al., 2007; Bird, 2007). Second only
to ATP, SAM is one of the most commonly used molecules
in living organisms. In experimental models of TBI, changes
in substrate methylation have been observed for histones and
cellular DNA, and have been suggested to contribute to ongoing
pathologies including reactive gliosis and impaired axonal
regeneration, as well as contribute to the development of chronic
neurodegeneration (Gao et al., 2006; Zhang et al., 2007; Portela
and Esteller, 2010; Lardenoije et al., 2015). Several studies have
evaluated the consequences of SAM supplementation to treat
diseases such as depression, Alzheimer’s disease, tauopathy,
liver disease, and various cancers (Purohit et al., 2007; Lu
et al., 2009; Papakostas, 2009; Lee et al., 2012; Montgomery
et al., 2014). For example, Papakostas (2009) tested if SAM
could be used as an adjunct therapy for depressed patients
who do not respond to serotonin reuptake inhibitors (SSRIs).
By comparison to patients maintained only on SSRIs, those
whose received SAM supplementation had higher Hamilton
Depression Rating Scale (HAM-D) response and remission rates
(Papakostas, 2009), indicating a reduction in depression severity
and an increase in wellness, respectively. As our measurements
indicate a significant reduction in the relative levels of SAM
in the plasma of sTBI patients, SAM supplementation may be
useful to treat some of the behavioral problems seen in these
patients.
As the brain has a high metabolic activity and high lipid
content, it is particularly vulnerable to oxidative damage.
Glutathione is the major antioxidant molecule, and a decrease
in its levels can exacerbate brain damage. Although intracellular
glutathione levels are relatively high, circulating levels of
glutathione are low, due to its extremely short half-life (ranging
from seconds to minutes; Wendel and Cikryt, 1980). This
likely contributed to our inability to detect glutathione in
our plasma samples. However, our findings that glutathione
precursors cysteine and glycine were significantly reduced, as
well as corresponding reductions in gamma-glutamyl amino
acids, suggest a decrease in its levels. It is therefore anticipated
that supplementation of precursors of glutathione may offer
protection. Consistent with this, systemic administration of
N-acetylcysteine, in combination with minocycline, improves
cognitive function in brain injured animals (Haber et al.,
2013).
Amino acids are thought to be transported into the cell
via their conversion to gamma-glutamyl amino acids, a
process dependent on glutathione (Orlowski and Meister,
1970). Gamma-glutamyl amino acids are then transported
into the cytosol where they are processed by gamma-
glutamylcyclotransferase to yield free amino acids and
5-oxoproline. As we observed decreased levels of several
gamma-glutamyl amino acids, as well as 5-oxoproline,
these findings suggest that intracellular transport of
amino acids via the gamma-glutamyl cycle is decreased.
These decreases, in conjunction with (or resulting from)
decreased amino acid levels, could further reduce the
intracellular availability of methionine and other amino
acids.
In addition to changes in methionine metabolism in sTBI
patients, we found a modest, but significant, decrease in
plasma methionine levels in mTBI as compared to HV
(Figure 1). This suggests that a decrease in methionine
following TBI may be related to injury severity. In addition to
methionine, we also observed TBI severity related changes in
the levels of alpha-ketobutyrate, 2-hydroxybutyrate (Figure 3)
and glycine (Figure 4). Interestingly, cysteine levels were
found to increase in the plasma of mTBI (Figure 3),
whereas its levels decreased in sTBI patients as compared
to HV. The reason for this divergence is not clear at
present.
A number of weakness need to be considered when
interpreting our results. As methionine and its metabolites were
measured in the plasma, the source of these molecules cannot
be ascertained. Additional weakness of the present study include
that the activity and levels of the enzymes for methionine
metabolism were not measured. Alterations in their activity,
in conjunction with decreased methionine levels, could have
given rise to the changes we observed. If supplementation
of protein/methionine restores the levels of SAM and other
metabolites, this would suggest that the metabolic enzymes of
methionine metabolism are not altered. However, this is yet
to be examined. Another weakness of our study is that the
consequence of SAM reduction on the methylation of cellular
proteins, DNA and phospholipids has not been determined.
A study by Yi et al. (2000) has reported that an increase
in plasma SAM levels is associated with hypomethylation of
DNA in lymphocytes. This suggests that the reduced plasma
SAM levels we measured in sTBI patients may result in the
hypermethylation of DNA and subsequent suppression of gene
expression. Finally, although we examined the influence of
gender on methionine and SAM levels, the number of females
in our study population was small. Thus, a larger group
of females would need to be assessed to truly evaluate if
there are gender differences in methionine metabolism after
TBI.
In summary, our results show that sTBI patients have low
levels of circulatingmethionine, and that methionine metabolites
generated via the transmethylation and transsulfuration cycle
are significantly reduced. In addition, flux through the gamma-
glutamyl cycle is decreased. As methionine and its metabolites
are critical for a number of cellular functions and cytoprotection,
decreases in their plasma levels may contribute to brain
injury pathology. Alternatively, these biochemical changes may
serve a protective function in the acute stage of injury,
and their persistence may be detrimental. The systemic
changes in methionine and metabolite levels we observed
may not only influence the function and pathology of the
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injured brain, but may alter the function of other organs
as well.
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